Wedbush has initiated coverage on Pharvaris N.V. (NASDAQ: PHVS), noting that the company stands out as one of the players with their strategy to develop and advance oral therapeutic options in both the acute and prophylactic settings for hereditary angioedema (HAE).
H.C. Wainwright initiated coverage on AngioDynamics Inc (NASDAQ: ANGO), noting that the company is debt-free and significantly undervalued compared to peers in a growing market.
Ikena Oncology Inc (NASDAQ: IKNA) is garnering attention with its oncology-focused pipeline, and the company's recent developments have raised optimism in the medical community.